Comparative Pharmacology
Head-to-head clinical analysis: LYSTEDA versus NUMBRINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYSTEDA versus NUMBRINO.
LYSTEDA vs NUMBRINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis.
Selective serotonin reuptake inhibitor (SSRI); increases synaptic serotonin by inhibiting SERT.
650 mg orally three times daily (total 3.9 g/day) for up to 5 days during menses.
2 mg/kg intravenously every 8 hours, max 150 mg per dose.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–2.5 hours). In patients with renal impairment, half-life is significantly prolonged (up to 20 hours in severe renal impairment).
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min)
Primarily renal excretion (>95% unchanged drug via glomerular filtration). Less than 5% is metabolized (mainly acylated derivative).
Renal: 70% unchanged; hepatic metabolism: 20%; fecal: 10%
Category C
Category C
Antifibrinolytic
Antifibrinolytic